Scholar Rock Holding Corp. Stock News

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK) today announced that it will report third quarter 2025 financial results on Friday, November 14, 2025, before the financial markets open. Following the release of the financials, the Company will host a live audio webcast with Scholar Rock management at 8:00 a.m. ET. To access the live audio webcast, please go to “Events and Present...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for children and adults with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that...

The big banks have started off the new earnings-reporting season, which means that insider buying of stocks could be muted for a while.

A potential delay in an important submission was the news item driving Scholar Rock's (SRRK -13.14%) share price down as the trading week kicked off. On Monday, the biotech's shares fell by more than 13% as a result, contrasting unfavorably with the 1.6% gain of the S&P 500 (^GSPC 1.56%).

An analyst's initiation of coverage was the spark that lit the fire underneath Scholar Rock's (SRRK 5.95%) equity on Thursday. The clinical-stage biotech's share price ballooned by 6% in response, on a trading day when the benchmark S&P 500 (^GSPC -0.28%) sagged by 0.3%.

People don't like to throw money into a sinking ship , and by that logic, insider buys in Wall Street can be an easy way to gauge how well a company might do in the coming quarters.

Scholar Rock Holding Corporation remains a Strong Buy despite a recent FDA Complete Response Letter for apitegromab in spinal muscular atrophy. The CRL was due to manufacturing site issues with Catalent Indiana LLC, not safety or efficacy, and a quick BLA resubmission is expected once resolved. Company has catalysts ahead, including EMA review for apitegromab in mid-2026 and promising phase 2 d...

Shares of Scholar Rock tumbled Tuesday after the FDA rejected the company's spinal muscular atrophy drug, citing concerns at a plant.